Almost contextually, Olsen et al. presented an alternative protocol to quantify oligodendrocyte-derived cfDNA in multiple sclerosis patients based on the analysis of DNAm of a different genomic region, namely the myelin oligodendrocyte glycoprotein (MOG) gene [9]. This evidence concerns the gene MOG and multiple sclerosis.